"It seems CSL is becoming the next MSB..." I think there are a few not-so-subtle differences between CSL and MSB, starting with the following: Shares on Issue (2024 vs 2014): CSL: 484m (2024) vs 474m (2014)... Increase = negligible MSB: 1.142bn (2024) vs 324m (2014) ...Increase = 3.5 times higher Cumulative Free Cash Flow (past 5 years): CSL: positive US$7.0bn MSB: negative $350m If a CSL trial fails (as has happened recently), the share price goes down a few percent If a MSB trial fails, the equity goes to donut. There are umpteen more differences, but in the interests of brevity I'll leave it there for consideration.
(20min delay)